FDA Clears Forward's FT2109 Psoriatic Arthritis Trial

Forward Therapeutics received U.S. clearance for a Phase 2 proof-of-concept study of its oral TNF signaling inhibitor, FT2109, in active psoriatic arthritis.

Updated on Nov. 5, 2026 in Arthritis

Isometric editorial illustration of a row of unlabeled oval tablets in teal and cream on a slate surface, one lifted slightly apart, in a clean geometric composition. — The FDA cleared Forward Therapeutics to begin a Phase 2 trial of oral FT2109 in about 210 adults with active psoriatic arthritis, a potential oral alternative to injected TNF inhibitors. AI Illustration. Upload story photo >

The U.S. Food and Drug Administration cleared Forward Therapeutics' Investigational New Drug application for a Phase 2 study of FT2109, a novel oral selective soluble TNF signaling inhibitor. The randomized, double-blind, placebo-controlled study will enroll approximately 210 adults with active psoriatic arthritis.

Why it matters

FT2109 is being developed as an oral alternative to biologic TNF inhibitors, which are currently given by injection or infusion. Clearance moves the candidate into patient testing, where its efficacy in psoriatic arthritis will be measured directly.

The candidate's evidence comes from a completed Phase 1 study in 90 healthy participants and preclinical models showing anti-inflammatory activity comparable to biologic TNF inhibition. Efficacy in patients remains unknown until the planned 210-patient Phase 2 study reports its Week 12 ACR20 results.

The players

Forward Therapeutics

Forward Therapeutics is the company developing FT2109 and announced the FDA clearance from its Boston headquarters.

U.S. Food and Drug Administration

The FDA is the federal agency responsible for reviewing and clearing Investigational New Drug applications before human clinical trials can begin in the United States.

The details

The Phase 2 study, designated FT2109-2201, will randomize adults with active psoriatic arthritis to FT2109 or placebo for 12 weeks, in addition to permitted background therapy. Two once-daily doses of FT2109 will be evaluated, and secondary assessments will cover safety, ACR50 and ACR70 responses, disease activity measures, and psoriasis severity.

November 5, 2026: FDA clears the IND application for the FT2109 Phase 2 study.
December 2026: Forward Therapeutics plans to begin the Phase 2 study.
Week 12 of treatment: Primary endpoint ACR20 response is assessed.

Big Picture

Biologic TNF inhibitors have been a mainstay of psoriatic arthritis treatment since they were approved for the condition, but they require injection or infusion. FT2109 seeks to bring TNF-pathway control to an oral, once-daily format, and the Phase 2 result will show whether that oral approach holds up in patients.

If FT2109 succeeds, patients with psoriatic arthritis could eventually have an oral, once-daily option instead of injected or infused TNF inhibitors. The Phase 2 trial will determine whether the drug provides meaningful improvement before any such option becomes available.

The takeaway

The FDA clearance moves FT2109 from preclinical and Phase 1 work into testing in patients with psoriatic arthritis. Readers should watch for the Week 12 ACR20 results, which will be the first evidence of whether the oral drug improves symptoms.

What happens next

Forward Therapeutics plans to initiate the Phase 2 FT2109-2201 study in December 2026, with the primary ACR20 endpoint assessed at Week 12 of treatment.